Linking β-catenin to androgen-signaling pathway

被引:292
作者
Yang, FJ
Li, XY
Sharma, M
Sasaki, CY
Longo, DL
Lim, B
Sun, ZJ
机构
[1] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA
[3] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA
[4] NIA, NIH, Immunol Lab, Baltimore, MD 21224 USA
关键词
D O I
10.1074/jbc.M111962200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The androgen-signaling pathway is important for the growth and progression of prostate cancer cells. The growth-promoting effects of androgen on prostate cells are mediated mostly through the androgen receptor (AR). There is increasing evidence that transcription activation by AR is mediated through interaction with other cofactors. beta-Catenin plays a critical role in embryonic development and tumorigenesis through its effects on E-cadherin-mediated cell adhesion and Wnt-dependent signal transduction. Here, we demonstrate that a specific protein-protein interaction occurs between beta-catenin and AR. Unlike the steroid hormone receptor coactivator 1 (SRC1), beta-catenin showed a strong interaction with AR but not with other steroid hormone receptors such as estrogen receptor alpha, progesterone receptor beta, and glucocorticoid receptor. The ligand binding domain of AR and the NH2 terminus combined with the first six armadillo repeats of beta-catenin were shown to be necessary for the interaction. Through this specific interaction, beta-catenin augments the ligand-dependent activity of AR in prostate cancer cells. Moreover, expression of E-cadherin in E-cadherin-negative prostate cancer cells results in redistribution of the cytoplasmic beta-catenin to the cell membrane and reduction of AR-mediated transcription. These data suggest that loss of E-cadherin can elevate the cellular levels of beta-catenin in prostate cancer cells, which may directly contribute to invasiveness and a more malignant tumor phenotype by augmenting AR activity during prostate cancer progression.
引用
收藏
页码:11336 / 11344
页数:9
相关论文
共 55 条
  • [1] beta-catenin is a target for the ubiquitin-proteasome pathway
    Aberle, H
    Bauer, A
    Stappert, J
    Kispert, A
    Kemler, R
    [J]. EMBO JOURNAL, 1997, 16 (13) : 3797 - 3804
  • [2] Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1
    Aoki, M
    Hecht, A
    Kruse, U
    Kemler, R
    Vogt, PK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) : 139 - 144
  • [3] Barker N, 2000, BIOESSAYS, V22, P961
  • [4] Functional interaction of beta-catenin with the transcription factor LEF-1
    Behrens, J
    vonKries, JP
    Kuhl, M
    Bruhn, L
    Wedlich, D
    Grosschedl, R
    Birchmeier, W
    [J]. NATURE, 1996, 382 (6592) : 638 - 642
  • [5] Linking colorectal cancer to Wnt signaling
    Bienz, M
    Clevers, H
    [J]. CELL, 2000, 103 (02) : 311 - 320
  • [6] BIRCHMEIER W, 1995, CANCER SURV, V24, P129
  • [7] NUCLEAR FACTOR RIP140 MODULATES TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR
    CAVAILLES, V
    DAUVOIS, S
    LHORSET, F
    LOPEZ, G
    HOARE, S
    KUSHNER, PJ
    PARKER, MG
    [J]. EMBO JOURNAL, 1995, 14 (15) : 3741 - 3751
  • [8] Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
    Cleutjens, KBJM
    vanEekelen, CCEM
    vanderKorput, HAGM
    Brinkmann, AO
    Trapman, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) : 6379 - 6388
  • [9] Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways
    Easwaran, V
    Pishvaian, M
    Salimuddin
    Byers, S
    [J]. CURRENT BIOLOGY, 1999, 9 (23) : 1415 - 1418
  • [10] Gayther SA, 1998, CANCER RES, V58, P4086